{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:33:39Z","timestamp":1786545219181,"version":"build-2736575974"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1038\/ajg.2012.42","type":"journal-article","created":{"date-parts":[[2012,5,3]],"date-time":"2012-05-03T03:12:32Z","timestamp":1336014752000},"page":"794-795","source":"Crossref","is-referenced-by-count":48,"title":["Ustekinumab for Peristomal Pyoderma Gangrenosum"],"prefix":"10.14309","volume":"107","author":[{"given":"Marianne","family":"Fahmy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Ramamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tissa","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-30-20210210","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1046\/j.1365-2133.2003.05294.x","article-title":"Infliximab for peristomal pyoderma gangrenosum.","volume":"148","author":"Mimouni","year":"2003","journal-title":"Br J Dermatol"},{"key":"R2-30-20210210","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1023\/B:DDAS.0000042245.20042.4f","article-title":"Treatment of pyoderma gangrenosum with infliximab in Crohns disease.","volume":"49","author":"Sapienza","year":"2004","journal-title":"Dig Dis Sci"},{"key":"R3-30-20210210","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-1223 monoclonal antibody for the treatment of psoriasis.","volume":"356","author":"Krueger","year":"2007","journal-title":"N Engl J Med"},{"key":"R4-30-20210210","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-1223 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"R5-30-20210210","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of ustekinumab, a human interleukin-1223 monoclonal antibody, in patients with moderate-to-severe Crohns disease.","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"R6-30-20210210","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S0016-5085(11)60443-5","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase2b Study or Ustekinumab, a human monoclonal antibody to IL-1223p40, in patients with moderately to severely active Crohns disease: results through week 22 from the certifi trial.","volume":"140","author":"Sandborn","year":"2011","journal-title":"Gastroenterology"},{"key":"R7-30-20210210","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/archdermatol.2011.168","article-title":"Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.","volume":"147","author":"Guenova","year":"2011","journal-title":"Arch Dermatol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg201242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201242","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201205000-00030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:38:16Z","timestamp":1786541896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201205000-00030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2012.42","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}